AGM Group Holdings Inc
Change company Symbol lookup
Select an option...
AGMH AGM Group Holdings Inc
DXLG Destination XL Group Inc
CENQ Cenaq Energy Corp
SJIJ South Jersey Industries Inc
CVS CVS Health Corp
HRTG Heritage Insurance Holdings Inc
ESUS ETRACS 2x Leveraged MSCI USA ESG Focus TR ETN
BSRR Sierra Bancorp
CO Global Cord Blood Corp
AHT-G Ashford Hospitality Trust Inc
Go

Financials : Capital Markets | Small Cap Growth
Based in Hong Kong
Company profile

AGM Group Holdings Inc. is a financial technology company and financial solutions provider. The Company mainly provides brokers and institutional clients with trading platform solutions and technologies. The Company operates mainly through three businesses, including online trading and computer support service business, which provides online trading platform application and computer program technical support and solution services; forex trading brokerage business, as well as program trading application technology and management service business. The Company operates its businesses in both the United Stated and global markets.

Closing Price
$1.61
Day's Change
-0.01 (-0.62%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.68
Day's Low
1.59
Volume
(Heavy Day)
Volume:
34,117

10-day average volume:
8,118
34,117

Merck stock ticks up after profit more than triples to beat expectations

6:45 am ET July 28, 2022 (MarketWatch)
Print

Shares of Merck & Co. Inc. (MRK) edged up 0.1% in premarket trading Thursday, after the drug maker reported second-quarter profit and sales that rose above expectations, and raised its full-year sales outlook slightly. Net income more than tripled, to $3.94 billion, or $1.55 a share, from $1.21 billion, or 48 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.87 beat the FactSet consensus of $1.70. Sales grew 28.0% to $14.59 billion, well above the FactSet consensus of $13.87 billion, as pharmaceutical sales rose 28% to $12.76 billion and animal health sales were little changed at $1.47 billion. Sales of Merck's largest drug Keytruda increased 26% to $5.25 billion to beat expectations of $5.03 billion. For 2022, the company narrowed its adjusted EPS guidance range to $7.25 to $7.35 from $7.24 to $7.36, but raised its sales guidance to $57.5 billion to $58.5 billion from $56.9 billion to $58.1 billion. The stock has gained 3.0% over the past three months through Wednesday, while the Dow Jones Industrial Average has lost 5.1%.

-Tomi Kilgore

	

(END) Dow Jones Newswires

July 28, 2022 06:45 ET (10:45 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.